A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Multicenter randomised phase II study of neoadjuvant therapy in HER2 positive early breast
cancer. Primary aim is to evaluate the cardiac toxicity of the combined treatment
(trastuzumab, docetaxel, bevacizumab, NPLD) in comparison to the standard therapy.